This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Graft versus host disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Graft-versus-host disease occurs when immunologically competent cells in the graft target antigens on cells in the recipient. It is generally a disease of T cell activity, and is a potential complication of any transplantation.

  • is a complication that often occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in up to 50% of cases, where donor T- and B cells derived from the graft recognize and attack host antigens (1)

The skin, liver, and gastrointestinal system are primarily affected. For unknown reasons, organs such as the kidney are often spared. Acute and chronic forms are recognised. The condition may be fatal especially if the recipient is immunologically impaired. Chronic disease is more likely in older patients.

A graft-versus-tumour effect is recognised and is associated with a more favourable outcome. Note however that it will be lost in grafts from identical twins.

The standard first-line chronic graft-versus-host disease (cGVHD) therapy is glucocorticoids (GCs) (2)


  • Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, Toubert A, Zeiser R, Galimberti S. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Front Immunol. 2020 Oct 9;11:578314.
  • Zeiser R. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2023 Feb 17:JCO2202256.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page